Commonly known as atopic dermatitis, eczema is "the itch that rashes," says Dr. Shi, meaning that an itching sensation often occurs first followed by a visible rash that develops after scratching.

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

Seborrheic dermatitis is positively associated with a range of epithelial barrier diseases, including dermatologic, respiratory, gastrointestinal, and ocular diseases.

Please provide your email address to receive an email when new articles are posted on . The FDA will review a new drug application for roflumilast foam 0.3% to treat seborrheic dermatitis in patients ...

If treating flakes has always left you, er, scratching your head, you’re not alone—and finding the best dandruff treatments starts with understanding what’s actually causing them. “Dandruff is a very ...

Seborrheic dermatitis is associated with other epithelial barrier diseases of the skin and beyond, including the respiratory, ...

Seborrheic dermatitis may disrupt the skin barrier, potentially exposing patients to other epithelial barrier diseases (EBDs) across various organ systems. A large cohort study found positive ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...